The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI (peptide‐Fc fusion protein) leads to lower progression‐free survival (PFS) compared with chemotherapy alone (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (low certainty).
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
The review found no eligible studies for this question.
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).